August 17, 2017
Are All Treatments Created Equal?
The last five years have seen a flurry of drug approvals for new and highly effective hepatitis C (HCV) medications that don't require peginterferon and ribavirin (Rebetol) for most patients. These approvals have come at an almost breakneck pace. For example, simeprevir (Olysio), one of the first new direct-acting antivirals (DAAs), has fallen out of favor less than four years after its approval.
In a major milestone, recent approvals of the two-drug combination sofosbuvir/velpatasvir (Epclusa) and the three-drug combo sofosbuvir/velpatasvir/voxilaprevir (Vosevi) mean the addition of new drugs that can treat all six HCV genotypes.
In addition to new treatments, new side effects have recently become apparent. In 2016, the U.S. Food and Drug Administration (FDA) warned that all DAAs carry the risk of reactivating hepatitis B, after two patients died and 24 cases of reactivation were reported. Physicians are now advised to screen for hepatitis B, and patients are urged to watch for side effects.
Considering the variety of treatments now available, what's the best DAA for each patient? Even with sofosbuvir/velpatasvir/voxilaprevir on the market, picking the right drug will depend on each patient's medical history, level of liver damage, coinfections and, to some extent, insurance coverage.
Image credit: TA2YO4NORI for iStock via Thinkstock.
|The Need for a Codified Hepatitis C Care Continuum|
|Could the HIV Treatment-as-Prevention Model Work for Hepatitis C?|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|Let's Advance the Conversation Among Black Women on HIV and PrEP|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|DACA, Immigrant Rights and the 'Larger Compassion' of the HIV Community|
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|